Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

BACKGROUND: Patients with chronic lymphocytic leukaemia (CLL) with TP53 aberrations respond poorly to first-line chemoimmunotherapy resulting in early relapse and short survival. We investigated the safety and activity of ibrutinib in previously untreated and relapsed or refractory CLL with TP53 abe...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Lancet Oncol
Hoofdauteurs: Farooqui, Mohammed Z H, Valdez, Janet, Martyr, Sabrina, Aue, Georg, Saba, Nakhle, Niemann, Carsten U, Herman, Sarah E M, Tian, Xin, Marti, Gerald, Soto, Susan, Hughes, Thomas E, Jones, Jade, Lipsky, Andrew, Pittaluga, Stefania, Stetler-Stevenson, Maryalice, Yuan, Constance, Lee, Yuh Shan, Pedersen, Lone B, Geisler, Christian H, Calvo, Katherine R, Arthur, Diane C, Maric, Irina, Childs, Richard, Young, Neal S, Wiestner, Adrian
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2014
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4342187/
https://ncbi.nlm.nih.gov/pubmed/25555420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)71182-9
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items